BR112020024261B8 - Composto de fórmula (ia) e composição farmacêutica - Google Patents

Composto de fórmula (ia) e composição farmacêutica

Info

Publication number
BR112020024261B8
BR112020024261B8 BR112020024261A BR112020024261A BR112020024261B8 BR 112020024261 B8 BR112020024261 B8 BR 112020024261B8 BR 112020024261 A BR112020024261 A BR 112020024261A BR 112020024261 A BR112020024261 A BR 112020024261A BR 112020024261 B8 BR112020024261 B8 BR 112020024261B8
Authority
BR
Brazil
Prior art keywords
formula
compound
pharmaceutical composition
opioid
compounds
Prior art date
Application number
BR112020024261A
Other languages
English (en)
Other versions
BR112020024261B1 (pt
BR112020024261A2 (pt
Inventor
N Confalone Pasquale
L Dax Scott
Original Assignee
Cersci Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cersci Therapeutics Inc filed Critical Cersci Therapeutics Inc
Publication of BR112020024261A2 publication Critical patent/BR112020024261A2/pt
Publication of BR112020024261B1 publication Critical patent/BR112020024261B1/pt
Publication of BR112020024261B8 publication Critical patent/BR112020024261B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

a invenção se refere a compostos da fórmula (i), composições contendo os mesmos e métodos para tratar e/ou diminuir a dor em um sujeito com necessidade dos mesmos. os compostos da fórmula (i) são eficazes para o tratamento de taquifilaxia induzida por opioides e hiperalgesia induzida por opioides.
BR112020024261A 2018-05-29 2019-05-20 Composto de fórmula (ia) e composição farmacêutica BR112020024261B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862677496P 2018-05-29 2018-05-29
US62/677,496 2018-05-29
PCT/US2019/033140 WO2019231739A1 (en) 2018-05-29 2019-05-20 Compounds for pain treatment, compositions comprising same, and methods of using same

Publications (3)

Publication Number Publication Date
BR112020024261A2 BR112020024261A2 (pt) 2021-02-23
BR112020024261B1 BR112020024261B1 (pt) 2022-05-03
BR112020024261B8 true BR112020024261B8 (pt) 2022-05-17

Family

ID=66770595

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020024261A BR112020024261B8 (pt) 2018-05-29 2019-05-20 Composto de fórmula (ia) e composição farmacêutica

Country Status (14)

Country Link
US (3) US11091473B2 (pt)
EP (1) EP3802524A1 (pt)
JP (1) JP2021525269A (pt)
KR (1) KR20210015892A (pt)
CN (1) CN112204025B (pt)
AU (1) AU2019279761A1 (pt)
BR (1) BR112020024261B8 (pt)
CA (1) CA3101738A1 (pt)
EA (1) EA202092691A1 (pt)
IL (1) IL278904A (pt)
MX (1) MX2020012805A (pt)
SG (1) SG11202011534YA (pt)
WO (1) WO2019231739A1 (pt)
ZA (1) ZA202007320B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022265960A1 (en) * 2021-06-13 2022-12-22 Daya Drug Discoveries, Inc. Prevention and treatment of neuronal damage with pyridoindolobenz[b, d] azepine compositions
WO2022266211A1 (en) * 2021-06-17 2022-12-22 Acadia Pharmaceuticals Inc. Methods of treating, ameliorating, and/or preventing osteoarthritic pain

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
FR2581063B1 (fr) 1985-04-30 1987-07-17 Chauvin Blache Lab Amino-2 thiazoles n-substitues, leur procede de preparation et leur application en therapeutique
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
ATE173159T1 (de) 1992-03-25 1998-11-15 Depomed Systems Inc Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe
US5840739A (en) 1992-11-16 1998-11-24 University Of Florida Research Foundation, Inc. Thiazoline acid derivatives
WO1997047285A1 (en) 1996-06-10 1997-12-18 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
AU729529B2 (en) 1997-06-06 2001-02-01 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
US6323219B1 (en) 1998-04-02 2001-11-27 Ortho-Mcneil Pharmaceutical, Inc. Methods for treating immunomediated inflammatory disorders
NZ518739A (en) 1999-11-02 2004-12-24 Depomed Inc Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
WO2001056544A2 (en) 2000-02-04 2001-08-09 Depomed, Inc. Shell-and-core dosage form approaching zero-order drug release
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
EP1401423A4 (en) 2001-05-29 2006-08-16 Depomed Dev Ltd METHOD FOR THE TREATMENT OF GASTROÖSOPHAGEAL REFLUX DISEASE AND NURSING ACID BREAKDOWN
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US7413751B2 (en) 2001-10-25 2008-08-19 Depomed, Inc. Methods of treatment using a gastric retained losartan dosage
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
AU2003263948A1 (en) * 2002-08-22 2004-03-11 University Of Florida Antioxidant and radical scavenging activity of synthetic analogs of desferrithiocin
PE20050159A1 (es) 2003-05-27 2005-04-19 Vertex Pharma Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa
GB0508463D0 (en) 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
TW200826937A (en) 2006-11-01 2008-07-01 Astrazeneca Ab New use
NL2003786C2 (en) 2009-11-11 2010-07-30 Medner B V COMPOSITION FOR TOPICAL APPLICATION, USES THEREOF, APPLICATOR DEVICE AND KIT OF PARTS.
EP2544542A4 (en) * 2010-03-10 2013-07-24 Galleon Pharmaceuticals Inc PAIN COMPOUNDS, COMPOSITIONS AND THEIR USE
EP3070084A1 (en) 2015-03-18 2016-09-21 Rottapharm Biotech S.r.l. New fyn kinase inhibitors
JP7104702B2 (ja) 2016-12-01 2022-07-21 プロメガ コーポレイション ５，５－二置換ルシフェリン及びルシフェラーゼ系アッセイにおけるそれらの使用

Also Published As

Publication number Publication date
US11091473B2 (en) 2021-08-17
KR20210015892A (ko) 2021-02-10
IL278904A (en) 2021-01-31
BR112020024261B1 (pt) 2022-05-03
US10844054B2 (en) 2020-11-24
CN112204025B (zh) 2022-05-31
MX2020012805A (es) 2021-02-15
SG11202011534YA (en) 2020-12-30
WO2019231739A1 (en) 2019-12-05
CA3101738A1 (en) 2019-12-05
US20200131170A1 (en) 2020-04-30
US20190367499A1 (en) 2019-12-05
US20220153731A1 (en) 2022-05-19
JP2021525269A (ja) 2021-09-24
BR112020024261A2 (pt) 2021-02-23
EP3802524A1 (en) 2021-04-14
CN112204025A (zh) 2021-01-08
AU2019279761A1 (en) 2020-12-10
EA202092691A1 (ru) 2021-04-21
ZA202007320B (en) 2022-04-28

Similar Documents

Publication Publication Date Title
BR112019006712A2 (pt) composto, composição farmacêutica, composição para uso no tratamento de uma doença, elemento implantável, e, dispositivo.
MX2022010947A (es) Compuestos arilo o heteroarilo sustituidos con amino como inhibidores de ehmt1 y ehmt2.
MX2019007234A (es) Compuestos heterociclicos sustituidos con amina como inhibidores de ehmt2 y metodos de uso de los mismos.
PH12018500642A1 (en) Anti-garp antibody
BR112018076534A2 (pt) compostos heterocíclicos como imunomoduladores
BR112018012756A2 (pt) compostos heterocíclicos como imunomoduladores
BR112018007526A2 (pt) compostos de benzolactama como inibidores de proteína quinase
BR112015022462A8 (pt) inibidores de ido, composição farmacêutica, método de inibição de atividade de indolamina 2,3-dioxigenase e uso dos referidos inibidores
PH12019502201A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
MX2019013735A (es) Antimitoscinas: inhibidores especificos de la biogenesis mitocondrial para erradicar celulas madre cancerosas.
MX2022013612A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas.
PH12020550986A1 (en) Heterocyclylamino-substituted triazoles as modulators of rho-associated protein kinase
MX2017012545A (es) Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
BR112018071408A2 (pt) “composto inibidor de rip2 quinase, composição farmacêutica, usos de um composto e de uma combinação, e, combinação
MX2021012501A (es) Inhibidores de complejo represivo polycomb 2 (prc2).
BR112018006545A2 (pt) ?composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição?
BR112018070536A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
BR112016030730A8 (pt) composto
BR112022008365A2 (pt) Inibidores de cd73
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
BR112018070514A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
BR112020024261B8 (pt) Composto de fórmula (ia) e composição farmacêutica
BR112014019704A8 (pt) Compostos inibidores de hsp90 c-terminais, composição farmacêutica compreendendo os ditos compostos e uso dos mesmos para o tratamento ou prevenção de um distúrbio neurodegenerativo
BR112018072298A2 (pt) tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/05/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2678 DE 03/05/2022 QUANTO AO TITULO.